Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Galectin Therapeutics Inc.NASDAQ: GALT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $5.05M (cash outflow) fell 47.6% year over year, behind the -41.9% change in trailing-twelve-month net income. Sequentially, it fell 8.3% from the prior quarter. Over 3 fiscal years it compounded at -7.4% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$23.64M (-23.3%) for the fiscal year ending Dec 2026, a step up from the -34.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.05M-8.3% QoQ
- Last fiscal yearDec 2025
- -$30.84M-34.5% YoY
- LTMMar 2026
- -$26.25M-41.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -47.6% | -21.3% | +26.3 pp |
| 1 year | -34.5% | -23.3% | +11.1 pp |
| 3-year CAGR | -7.4% | +30.0% | +37.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (30.84M) USD
- Year-over-year change
- +34.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (30.84M) | +34.5% |
| FY2024 | 2024-12-31 | (47.05M) | -14.6% |
| FY2023 | 2023-12-31 | (41.07M) | -5.9% |
| FY2022 | 2022-12-31 | (38.78M) | -27.0% |
| FY2021 | 2021-12-31 | (30.53M) | — |
Net Income vs competitors
How GALT compares with its peers on the latest reported figures
- GALT's LTM Mar 2026 net income of $26.25M is the smallest of the 10 companies compared; the peer median is $91.08M.
- Its year-over-year change of -41.9% is the lowest of 9, against a peer median of +21.4%.
- Over three fiscal years its annual growth of -7.4% compares with a peer median of +8.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $209.38M | -18.9% | +0.2% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $126.85M | +58.8% | +68.6% | — |
| LTM Mar 2026 | $112.39M | +18.7% | +21.8% | — | |
| LTM Mar 2026 | $103.82M | +3.1% | -8.5% | 5605.9% | |
| LTM Mar 2026 | $91.08M | +0.9% | +1.3% | 253002.8% | |
| LTM Mar 2026 | $69.71M | +24.0% | +3.3% | — | |
| LTM Dec 2025 | $42.63M | +34.3% | +8.1% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $39.17M | — | +20.7% | — |
| LTM Mar 2026 | $35.1M | +30.0% | +33.8% | — | |
| LTM Mar 2026 | $26.25M | -41.9% | -7.4% | — | |
| Peer median (excluding GALT) | $91.08M | +21.4% | +8.1% | 129304.3% | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.08M | 2.87M | 2.26M | 2.45M | 1.66M |
| Change in Working Capital | 3.75M | 4.97M | 4.68M | 2.28M | 609K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.69M | 4.24M | 2.67M | (2.07M) | (6.04M) |
| Other Working Capital | 65K | 724K | 2.01M | 4.36M | 6.65M |
| Other Non-Cash Items | 351K | (147K) | 1.13M | 512K | 4.64M |
| Operating Cash Flow | (24.31M) | (31.06M) | (32.97M) | (41.77M) | (23.88M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 30M | 10M | 30M | 30M | 21M |
| Common Stock Issued | 6.81M | 0 | 0 | 1.23M | 5.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (171K) | 0 | 0 | (91K) | 0 |
| Other Financing Activities | 171K | 0 | 10.03M | 91K | 0 |
| Financing Cash Flow | 36.81M | 10M | 40.03M | 31.23M | 26.48M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 12.51M | (21.06M) | 7.07M | (10.54M) | 2.6M |
| Free Cash Flow | (24.31M) | (31.06M) | (32.97M) | (41.77M) | (23.88M) |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.